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The current standard of therapy for patients with ad-vanced non-small cell lung cancer (NSCLC) is plati-
num-based doublet chemotherapy. Therapeutic results are
far from satisfactory: survival has reached a plateau
at a median of 9 to 11 months in the recently published
phase III trials. One way to improve on these results is to
personalize treatment, among others based on tumor or
molecular characteristics. Examples of these are the use of
pemetrexed for nonsquamous NSCLC1 and tyrosine kinase
inhibitors for tumors harboring epidermal growth factor
receptor (EGFR) mutations.2 In NSCLC, the most fre-
quently occurring somatic mutations are located in three
codons of the K-Ras gene.3 Constitutional activation of
K-Ras leads to signaling through the Raf-Mek-Erk path-
way, which is implicated in cellular growth and survival
pathways. Treatment options for patients who have K-Ras
mutated tumors are limited as these are believed to be poor
responders to cytotoxic chemotherapy and refractory to
EGFR tyrosine kinase inhibitors.4
Sorafenib, a multitargeted tyrosine kinase in-
hibitor, inhibits among others the Ras-Raf pathway. In a
recent large scale sequencing study, more than 1000 so-
matic mutations in 188 human lung adenocarcinomas were
discovered. In this study, Sorafenib was suggested as
potential treatment option.5 Sorafenib has been evaluated
in unselected advanced patients with NSCLC both as a
single agent and in conjuncture with platinum doublet
chemotherapy as first-line treatment. The results of these
studies are not equivocal: although the single-agent studies
showed some activity of sorafenib in all lines of tre-
atment, the ESCAPE phase III trial failed to improve
survival when sorafenib was added to the commonly used
paclitaxel-carboplatin doublet. We hypothesized that se-
lecting patients with NSCLC with K-Ras mutated tu-
mors would enhance the clinical efficacy of sorafenib.
Herein, we report our initial experience with this app-
roach. This proof of concept study was approved by the
Medical Ethical Committees of the two participating med-
ical centers.
K-Ras mutation analyses was performed on DNA
extracted from paraffin-embedded tumor tissue by manual
dissection and overnight incubation with proteinase K.
Subsequently, high-resolution melting and sequencing mu-
tations were confirmed.6 Ten patients with advanced
NSCLC, progressive after at least one line of chemother-
apy and harboring a K-Ras mutation were offered treat-
ment with sorafenib 200 mg or 400 mg twice daily, which
was administered until progression or unacceptable toxic-
ity. Response was evaluated every 4 to 6 weeks by com-
puted tomography scanning of the chest using RECIST
criteria. Ten patients with a K-Ras mutation, 4 G12V, 4
G12C, 1 G12A, and 1 G13S including six women and four
men with good performance status (1 performance status
[PS] 0, 7 PS 1, and 2 PS 2) and mean age of 56 years
(range 44–70) were treated. All patients were current or
exsmokers and were pretreated with at least one chemo-
therapy regimen. Details on patient characteristics and
response to previous chemotherapy regimen are provided
in the Table 1.
The observed toxicity of treatment was not different
from that previously reported in single-agent trials of
sorafenib. The most troublesome toxicity consisted of
hand-foot syndrome although this did not exceed
grade 2. Three patients interrupted treatment for diarrhea
grade II, depression, and infection in a cavitating tumor.
Surprisingly, three partial remissions (PRs) and three min-
imal responses (MRs) 5 of which were associated with
tumor cavitation were observed. The median progression-
free survival was 3 months (95% CI: 2.2–3.8 months).
In our opinion, based on these results, further testing
of sorafenib in phase II setting in treatment resistant K-Ras
mutated NSCLC is warranted.
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TABLE 1. Patient Characteristics and Response to Therapy
Sex Age PS Stage Hist. K-Ras mut Prior CT
Best
Response Response Sorafenib PFS (mo) Cavitation
M 70 1 IV BAC G12V 4 lines MR MR 3 
F 48 2 IV SSC G12V 1 line PD PD 2
M 70 1 IV BAC G12V 2 lines PD PR 8 
F 44 1 IV Adeno G12C 1 line PD SD 3
F 47 1 IV Adeno G12C 2 lines SD PR 5
M 55 1 IV LC G13S 3 lines PR PR 6
F 62 0 IV LC G12V 4 lines PR MR 5
F 54 1 IV Adeno G12A 2 lines SD MR 1.5 
M 56 2 IV Adeno G12C 4 lines Unknown SD 2 
F 61 1 IV Adeno G12C 3 lines PD SD 2.5 
BAC, broncho alveolar cell carcinoma; CT, computed tomography; LC, large cell carcinoma; PD, progressive disease; PFS, progression-free survival; SCC, squamous cell
carcinoma; SD, stable disease.
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